`
`_________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_________________________________
`
`
`NOVEN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`_________________________________
`
`
`Inter Partes Review No.: 2014-00550
`U.S. Patent No. 6,335,031
`
`_________________________________
`
`
`Stipulated Protective Order
`
`This stipulated protective order governs the treatment and filing of
`
`confidential information, including documents and testimony.
`
`1.
`
`Confidential information shall be clearly marked “PROTECTIVE
`
`ORDER MATERIAL.”
`
`2.
`
`Access to confidential information is limited to the following
`
`individuals who have executed the acknowledgment appended to this order:
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 1 of 9
`
`
`
`(A) Party Representatives. Representatives of record for a party in
`
`the proceeding.
`
`(B) Experts. Retained experts of a party in the proceeding who
`
`further certify in the Acknowledgement that they are not a competitor
`
`to any party, or a consultant for, or employed by, such a competitor
`
`with respect to the subject matter of the proceeding.
`
`(C)
`
`In-house counsel. Peter Waibel and Tim Ohnemuller as in-
`
`house counsel for Patent Owners, and Jeff Mihm as in-house counsel
`
`for Petitioner, provided that Messrs. Mihm, Waibel, and Ohnemuller
`
`do not have and will not assume responsibility for the prosecution of
`
`patent applications claiming rivastigmine, compositions or devices
`
`containing rivastigmine, methods of making rivastigmine or
`
`rivastigmine-containing products, or methods of using rivastigmine.
`
`Messrs. Mihm, Waibel, and Ohnemuller may receive “PROTECTIVE
`
`ORDER MATERIAL” of the opposing party only if such material is
`
`contained in or attached to documents filed or to be filed with the
`
`Board or if such documents are marked at a deposition taken in
`
`connection with this proceeding.
`
`(D) Other Employees of a Party. Employees, consultants or other
`
`persons performing work for a party, other than in-house counsel and
`
`
`
`1
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 2 of 9
`
`
`
`in-house counsel’s support staff, who sign the Acknowledgement
`
`shall be extended access to confidential information only upon
`
`agreement of the parties or by order of the Board upon a motion
`
`brought by the party seeking to disclose confidential information to
`
`that person. The party opposing disclosure to that person shall have
`
`the burden of proving that such person should be restricted from
`
`access to confidential information.
`
`(E) The Office. Employees and representatives of the Office who
`
`have a need for access to the confidential information shall have such
`
`access without the requirement to sign an Acknowledgement. Such
`
`employees and representatives shall include the Director, members of
`
`the Board and their clerical staff, other support personnel, court
`
`reporters, and other persons acting on behalf of the Office.
`
`(F)
`
`Support Personnel. Administrative assistants, clerical staff,
`
`court reporters and other support personnel of the foregoing persons
`
`who are reasonably necessary to assist those persons in the proceeding
`
`shall not be required to sign an Acknowledgement, but shall be
`
`informed of the terms and requirements of the Protective Order by the
`
`person they are supporting who receives confidential information.
`
`
`
`2
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 3 of 9
`
`
`
`3.
`
`Persons receiving confidential information shall use reasonable efforts
`
`to maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which
`
`persons not authorized to receive the information shall not have
`
`access;
`
`(B) Otherwise using reasonable efforts to maintain the
`
`confidentiality of the information, which efforts shall be no less
`
`rigorous than those the recipient uses to maintain the confidentiality
`
`of information not received from the disclosing party;
`
`(C) Ensuring that support personnel of the recipient who have
`
`access to the confidential information understand and abide by the
`
`obligation to maintain the confidentiality of information received that
`
`is designated as confidential; and
`
`(D) Limiting the copying of confidential information to a
`
`reasonable number of copies needed for conduct of the proceeding
`
`and maintaining a record of the locations of such copies.
`
`4.
`
`Persons receiving confidential information shall use the following
`
`procedures to maintain the confidentiality of the information:
`
`(A) Documents and Information Filed With the Board.
`
`
`
`3
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 4 of 9
`
`
`
`(i) A party may file documents or information with the
`
`Board under seal, together with a non-confidential description
`
`of the nature of the confidential information that is under seal
`
`and the reasons why the information is confidential and should
`
`not be made available to the public. The submission shall be
`
`treated as confidential and remain under seal, unless, upon
`
`motion of a party and after a hearing on the issue, or sua sponte,
`
`the Board determines that the documents or information do not
`
`to qualify for confidential treatment.
`
`(ii) Where confidentiality is alleged as to some but not all of
`
`the information submitted to the Board, the submitting party
`
`shall file confidential and nonconfidential versions of its
`
`submission, together with a Motion to Seal the confidential
`
`version setting forth the reasons why the information redacted
`
`from the non-confidential version is confidential and should not
`
`be made available to the public. The nonconfidential version of
`
`the submission shall clearly indicate the locations of
`
`information that has been redacted. The confidential version of
`
`the submission shall be filed under seal. The redacted
`
`information shall remain under seal unless, upon motion of a
`
`
`
`4
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 5 of 9
`
`
`
`party and after a hearing on the issue, or sua sponte, the Board
`
`determines that some or all of the redacted information does not
`
`qualify for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties.
`
`Information designated as confidential that is disclosed to another
`
`party during discovery or other proceedings before the Board shall be
`
`clearly marked as “PROTECTIVE ORDER MATERIAL” and shall
`
`be produced in a manner that maintains its confidentiality.
`
`
`
`5
`
`
`
`
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 6 of 9
`
`
`
`Date: March 31, 2015
`
`
`
`By:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Raymond R. Mandra/
`Raymond R. Mandra
`Registration No. 34,382
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA,
`HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`/Michael K. Levy/
`Michael K. Levy
`Counsel for Petitioner
`KENYON & KENYON LLP
`One Broadway
`New York, NY 10004-1007
`Tel. 212-425-7200
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 7 of 9
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_________________________________
`
`
`NOVEN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`_________________________________
`
`
`Inter Partes Review No.: 2014-00550
`U.S. Patent No. 6,335,031
`
`_________________________________
`
`
`Standard Acknowledgment for Access to Protective Order Material
`
`
`
`I , affirm that I have
`
`read the Protective Order; that I will abide by its terms; that I will use the
`
`confidential information only in connection with this proceeding and for no other
`
`purpose; that I will only allow access to support staff who are reasonably necessary
`
`to assist me in this proceeding; that prior to any disclosure to such support staff I
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 8 of 9
`
`
`
`informed or will inform them of the requirements of the Protective Order; that I am
`
`personally responsible for the requirements of the terms of the Protective Order
`
`and I agree to submit to the jurisdiction of the Office and the United States District
`
`Court for the Eastern District of Virginia for purposes of enforcing the terms of the
`
`Protective Order and providing remedies for its breach.
`
`
`_______________________
`Signature
`
`
`_______________________
`Date
`
`
`
`
`2
`
`NOVARTIS EXHIBIT 2056
`Noven v. Novartis and LTS Lohmann
`IPR2014-00550
`Page 9 of 9
`
`